Back

Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Treatment of transthyretin amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Francesco Cappelli

Careggi University Hospital (AOUC), Florence (Italy)

7 More presentations in this session

Presentation thumbnail
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis
Doctor V. Castiglione (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Optimizing treatment strategies for transthyretin amyloid cardiomyopathy: a comprehensive Bayesian network meta-analysis of disease-specific therapies
Doctor M. Rahman (Flushing, US)
Abstract Slides Video
Presentation thumbnail
Diagnostic, therapeutic and prognostic implications of carpal tunnel syndrome and spinal stenosis in wild-type transthyretin cardiac amyloidosis.
Doctor P. Debonnaire (Brugge, BE)
Abstract Slides Video
Presentation thumbnail
Effects of targeted transthyretin amyloid cardiomyopathy treatments on clinical outcomes a meta-analysis
Doctor T. Tsampras (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Which patients did recent trials in transthyretin amyloid cardiomyopathy select? - insights from a prospective patient registry
Doctor L. Schmid (Vienna, AT)
Abstract Slides Video

Access the full session

Session thumbnail
Treatment of transthyretin amyloidosis

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Effect of acoramidis on functional capacity and quality of life in patients with variant ATTR-CM: results from ATTRibute-CM
thumbnail
Congress Presentation
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM
thumbnail
Congress Presentation
Acoramidis significantly improves NT-proBNP indices that indicate ATTR-CM disease progression and predict subsequent mortality: insights from the ATTRibute-CM study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources